Ma Xiao, Huang Tengda, Li Xiaoquan, Zhou Xinyi, Pan Hongyuan, Du Ao, Zeng Yong, Yuan Kefei, Wang Zhen
Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Front Med (Lausanne). 2024 Sep 20;11:1428973. doi: 10.3389/fmed.2024.1428973. eCollection 2024.
Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has caused a global pandemic. Gastric cancer (GC) poses a great threat to people's health, which is a high-risk factor for COVID-19. Previous studies have found some associations between GC and COVID-19, whereas the underlying molecular mechanisms are not well understood.
We employed bioinformatics and systems biology to explore these links between GC and COVID-19. Gene expression profiles of COVID-19 (GSE196822) and GC (GSE179252) were obtained from the Gene Expression Omnibus (GEO) database. After identifying the shared differentially expressed genes (DEGs) for GC and COVID-19, functional annotation, protein-protein interaction (PPI) network, hub genes, transcriptional regulatory networks and candidate drugs were analyzed.
We identified 209 shared DEGs between COVID-19 and GC. Functional analyses highlighted immune-related pathways as key players in both diseases. Ten hub genes (, , , , , , , , , ) were identified. The transcription factor/gene and miRNA/gene interaction networks identified 38 transcription factors (TFs) and 234 miRNAs. More importantly, we identified ten potential therapeutic agents, including ciclopirox, resveratrol, etoposide, methotrexate, trifluridine, enterolactone, troglitazone, calcitriol, dasatinib and deferoxamine, some of which have been reported to improve and treat GC and COVID-19.
This research offer valuable insights into the molecular interplay between COVID-19 and GC, potentially guiding future therapeutic strategies.
2019年冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种传染病，已导致全球大流行。胃癌（GC）对人们的健康构成巨大威胁，是COVID-19的一个高危因素。先前的研究发现了GC与COVID-19之间的一些关联，但其潜在的分子机制尚不清楚。
我们采用生物信息学和系统生物学方法来探索GC与COVID-19之间的这些联系。从基因表达综合数据库（GEO）中获取了COVID-19（GSE196822）和GC（GSE179252）的基因表达谱。在确定了GC和COVID-19的共享差异表达基因（DEG）后，对其进行了功能注释、蛋白质-蛋白质相互作用（PPI）网络、枢纽基因、转录调控网络和候选药物分析。
我们在COVID-19和GC之间鉴定出209个共享DEG。功能分析突出了免疫相关途径在这两种疾病中都是关键因素。鉴定出了10个枢纽基因（，，，，，，，，，）。转录因子/基因和miRNA/基因相互作用网络鉴定出38个转录因子（TF）和234个miRNA。更重要的是，我们鉴定出了10种潜在治疗药物，包括环吡酮、白藜芦醇、依托泊苷、甲氨蝶呤、曲氟尿苷、肠内酯、曲格列酮、骨化三醇、达沙替尼和去铁胺，其中一些已被报道可改善和治疗GC及COVID-19。
本研究为COVID-19与GC之间的分子相互作用提供了有价值的见解，可能为未来的治疗策略提供指导。
